Natural Health Trends (NHTC) 10-Q 1 Nov 17 2017 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Oct. 27, 2017
Document And Entity Information
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Entity Registrant Name	NATURAL HEALTH TRENDS CORP.
Entity Central Index Key	912,061
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Common Stock, Shares Outstanding (in shares)		11,341,890
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3
Amendment Flag	false

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 126,953	$ 125,921
Inventories	10,632	11,257
Other current assets	2,961	4,066
Total current assets	140,546	141,244
Property and equipment, net	1,225	1,388
Goodwill	1,764	1,764
Restricted cash	3,092	2,963
Other assets	772	692
Total assets	147,399	148,051
Current liabilities:
Accounts payable	1,023	2,145
Income taxes payable	1,064	663
Accrued commissions	10,443	13,611
Other accrued expenses	8,545	14,989
Deferred revenue	3,568	4,948
Amounts held in eWallets	16,178	19,165
Other current liabilities	1,705	1,633
Total current liabilities	42,526	57,154
Deferred Tax Liabilities, Net, Noncurrent	285	268
Long-term incentive	6,730	8,190
Total liabilities	49,541	65,612
Commitments and contingencies (Note 8)
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at September 30, 2017 and December 31, 2016	13	13
Additional paid-in capital	86,674	86,574
Retained earnings	52,457	38,548
Accumulated other comprehensive loss	(716)	(807)
Treasury stock, at cost; 1,637,524 and 1,692,218 shares at September 30, 2017 and December 31, 2016, respectively	(40,570)	(41,889)
Total stockholders’ equity	97,858	82,439
Total liabilities and stockholders’ equity	$ 147,399	$ 148,051

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	12,979,414	12,979,414
Treasury stock, shares	1,637,524	1,692,218

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income Statement [Abstract]
Net sales	$ 40,132	$ 70,679	$ 151,471	$ 225,416
Cost of sales	8,183	13,627	29,221	42,966
Gross profit	31,949	57,052	122,250	182,450
Operating expenses:
Commissions expense	15,802	30,578	63,842	103,547
Selling, general and administrative expenses	7,495	11,170	23,621	34,505
Depreciation and amortization	138	96	414	276
Total operating expenses	23,435	41,844	87,877	138,328
Income from operations	8,514	15,208	34,373	44,122
Other income, net	(12)	48	224	40
Income before income taxes	8,502	15,256	34,597	44,162
Income tax provision	1,164	2,699	6,531	8,124
Net income	$ 7,338	$ 12,557	$ 28,066	$ 36,038
Net income per common share:
Basic (in dollars per share)	$ 0.65	$ 1.12	$ 2.50	$ 3.15
Earnings Per Share, Diluted	$ 0.65	$ 1.12	$ 2.49	$ 3.14
Weighted-average number of common shares outstanding:
Basic (in shares)	11,258	11,209	11,244	11,437
Diluted (in shares)	11,276	11,232	11,269	11,463
Cash dividends declared per share:
Common (in dollars per share)	$ 0.36	$ 0.07	$ 1.25	$ 0.18

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Statement of Comprehensive Income [Abstract]
Net income	$ 7,338	$ 12,557	$ 28,066	$ 36,038
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment	196	(54)	359	(329)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax	0	0	(258)	132
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	196	(54)	101	(197)
Unrealized gains (losses) on available-for-sale securities	(5)	(11)	(10)	(4)
Comprehensive income	$ 7,529	$ 12,492	$ 28,157	$ 35,837

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 28,066	$ 36,038
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	414	276
Stock-based compensation	26	94
Cumulative Translation Adjustment Realized In Net Income	(258)	132
Changes in assets and liabilities:
Inventories	590	(4,382)
Other current assets	1,164	(1,244)
Other assets	(61)	(91)
Accounts payable	(1,121)	252
Income taxes payable	392	278
Accrued commissions	(3,143)	(1,045)
Other accrued expenses	(5,064)	3,459
Deferred revenue	(1,364)	222
Amounts held in eWallets	(2,856)	3,098
Other current liabilities	51	26
Long-term incentive	(1,498)	(825)
Net cash provided by operating activities	15,338	36,288
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(238)	(679)
Net cash used in investing activities	(238)	(679)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repurchase of common stock	0	(23,704)
Dividends paid	(14,157)	(2,049)
Net cash used in financing activities	(14,157)	(25,753)
Effect of exchange rates on cash and cash equivalents	89	(270)
Net increase in cash and cash equivalents	1,032	9,586
CASH AND CASH EQUIVALENTS, beginning of period	125,921	104,914
CASH AND CASH EQUIVALENTS, end of period	126,953	114,500
SUPPLEMENTAL DISCLOSURES OF OTHER CASH FLOW INFORMATION:
Income Taxes Paid	5,690	7,994
Issuance of treasury stock for employee awards, net	$ 1,393	$ 1,741

NATURE OF OPERATIONS AND BASIS

NATURE OF OPERATIONS AND BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF OPERATIONS AND BASIS OF PRESENTATION	NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION Nature of Operations Natural Health Trends Corp. (the “Company”), a Delaware corporation, is an international direct-selling and e-commerce company headquartered in Rolling Hills Estates, California. Subsidiaries controlled by the Company sell personal care, wellness, and “quality of life” products under the “NHT Global” brand. The Company’s wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Singapore, Malaysia and Vietnam; South Korea; Japan; and Europe. The Company also operates in Russia and Kazakhstan through an engagement with a local service provider. Basis of Presentation The unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. As a result, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial information for the interim periods presented. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the fiscal year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s 2016 Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 10, 2017. Principles of Consolidation

ACCOUNTING PRONOUNCEMENTS ACCOU

ACCOUNTING PRONOUNCEMENTS ACCOUNTING PRONOUNCEMENTS (Notes)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	ACCOUNTING PRONOUNCEMENTS In November 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-18, Statement of Cash Flows - Restricted Cash , that requires amounts generally described as restricted cash or restricted cash equivalents be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The new standard will be effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, and early adoption is permitted. The adoption of this guidance is not expected to have a material impact on the Company’s consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting , that simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The new standard was effective for fiscal years beginning after December 15, 2016, including interim periods within those annual years, and early adoption was permitted. The Company adopted this guidance as of the quarter ended March 31, 2017. The adoption of this guidance did not have a material effect on the Company’s consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases , that requires organizations that lease assets, referred to as “lessees”, to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases with lease terms of more than 12 months. ASU 2016-02 will also require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases and will include qualitative and quantitative requirements. The new standard will be effective for fiscal years beginning after December 15, 2018, including interim periods within those annual years, and early application is permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements. In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes . Under this guidance, entities are required to present deferred tax assets and deferred tax liabilities as noncurrent in a classified balance sheet. This guidance was effective for annual and interim periods beginning after December 15, 2016, with early adoption permitted. Entities were permitted to adopt this guidance either prospectively or retrospectively. The Company elected to early adopt this guidance prospectively as of the quarter ended December 31, 2016. In July 2015, the FASB issued ASU No. 2015-11, Inventory: Simplifying the Measurement of Inventory. Under this guidance, inventory not measured using either the last in, first out (LIFO) or the retail inventory method are to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable cost of completion, disposal, and transportation. The new standard was effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years, with early adoption permitted. The Company adopted this guidance as of the quarter ended March 31, 2017. The adoption of this guidance did not have a material effect on the Company’s consolidated financial statements. In May 2014, the FASB issued ASU No. 2014-09, Revenue From Contracts With Customers , that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. It also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract. Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard. In July 2015, the FASB approved the deferral of the effective date for annual reporting periods that begin after December 15, 2017, including interim reporting periods. The adoption of this guidance is not expected to have a material impact on the Company’s consolidated financial statements.

NET INCOME PER COMMON SHARE NET

NET INCOME PER COMMON SHARE NET INCOME PER COMMON SHARE	9 Months Ended
	Sep. 30, 2017
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	NET INCOME PER COMMON SHARE Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized and the amount of tax benefit that would be recorded in additional paid-in capital when the award becomes deductible are assumed to be used to repurchase shares. The following tables illustrate the computation of basic and diluted net income per common share for the periods indicated (in thousands, except per share data): Three Months Ended September 30, 2017 2016 Income (Numerator) Shares (Denominator) Per Share Amount Income (Numerator) Shares (Denominator) Per Share Amount Basic net income per common share: Net income available to common stockholders $ 7,338 11,258 $ 0.65 $ 12,557 11,209 $ 1.12 Effect of dilutive securities: Non-vested restricted stock — 18 — 23 Diluted net income per common share: Net income available to common stockholders plus assumed conversions $ 7,338 11,276 $ 0.65 $ 12,557 11,232 $ 1.12 Nine Months Ended September 30, 2017 2016 Income (Numerator) Shares (Denominator) Per Share Amount Income (Numerator) Shares (Denominator) Per Share Amount Basic net income per common share: Net income available to common stockholders $ 28,066 11,244 $ 2.50 $ 36,038 11,437 $ 3.15 Effect of dilutive securities: Non-vested restricted stock — 25 — 26 Diluted net income per common share: Net income available to common stockholders plus assumed conversions $ 28,066 11,269 $ 2.49 $ 36,038 11,463 $ 3.14

BALANCE SHEET COMPONENTS Balanc

BALANCE SHEET COMPONENTS Balance Sheet Components	9 Months Ended
	Sep. 30, 2017
Balance Sheet Components [Abstract]
Supplemental Balance Sheet Disclosures [Text Block]	BALANCE SHEET COMPONENTS The components of certain balance sheet amounts are as follows (in thousands): September 30, 2017 December 31, 2016 Cash and cash equivalents: Cash $ 53,536 $ 52,453 Cash equivalents 73,417 73,468 $ 126,953 $ 125,921 Other accrued expenses: Sales returns $ 574 $ 1,632 Employee-related 6,236 10,541 Warehousing, inventory-related and other 1,735 2,816 $ 8,545 $ 14,989

FAIR VALUE MEASUREMENTS (Notes)

FAIR VALUE MEASUREMENTS (Notes)	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	FAIR VALUE MEASUREMENTS As of September 30, 2017 , cash and cash equivalents include the Company’s investments in debt securities, comprising municipal notes and bonds and corporate debt, money market funds and time deposits. The Company considers all highly liquid investments with original maturities of three months or less when purchased and have insignificant interest rate risk to be cash equivalents. Debt securities classified as cash equivalents are required to be accounted for in accordance with ASC 320, Investments - Debt and Equity Securities . As such, the Company determined its investments in debt securities held at September 30, 2017 should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in accumulated other comprehensive income in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income. Realized gains and losses, as well as interest income, are also included in other income. The fair values of securities are based on quoted market prices. The carrying amounts of the Company’s financial instruments, including cash and cash equivalents and accounts payable, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents. The Company’s cash equivalents are valued based on level 1 inputs which consist of quoted prices in active markets. Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value. The Company has elected to not fair value existing eligible items. Available-for-sale investments included in cash equivalents at the end of each period were as follows (in thousands): September 30, 2017 December 31, 2016 Adjusted Cost Gross Unrealized Gains (Losses) Fair Value Adjusted Cost Gross Unrealized Losses Fair Value Municipal bonds and notes $ 2,751 $ 1 $ 2,752 $ 43,490 $ — $ 43,490 Corporate debt securities 24,194 (13 ) 24,181 1,673 (2 ) 1,671 Financial institution instruments 46,484 — 46,484 28,307 — 28,307 Total available-for-sale investments $ 73,429 $ (12 ) $ 73,417 $ 73,470 $ (2 ) $ 73,468

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	9 Months Ended
	Sep. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	. STOCKHOLDERS’ EQUITY Dividends The following table summarizes the Company’s cash dividend activity for the nine months ended September 30, 2017 (in thousands, except per share data): Declaration Date Per Share Amount Record Date Payment Date July 31, 2017 (special) $ 0.25 $ 2,833 August 21, 2017 August 31, 2017 July 31, 2017 0.11 1,246 August 21, 2017 August 31, 2017 April 24, 2017 (special) 0.35 3,964 May 9, 2017 May 19, 2017 April 24, 2017 0.10 1,133 May 9, 2017 May 19, 2017 January 24, 2017 (special) 0.35 3,962 February 21, 2017 March 3, 2017 January 24, 2017 0.09 1,019 February 21, 2017 March 3, 2017 $ 1.25 $ 14,157 Declaration and payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors. Stock Repurchases On January 12, 2016, the Board of Directors authorized an increase to the Company’s stock repurchase program first approved on July 28, 2015 from $15.0 million to $70.0 million . Repurchases are expected to be executed to the extent that the Company’s earnings and cash-on-hand allow, and will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued. As of September 30, 2017 , $32.0 million of the $70.0 million stock repurchase program approved on July 28, 2015 and increased on January 12, 2016 remained available for future purchases, inclusive of related estimated income tax. Restricted Stock Stock-based compensation expense totaled $8,600 and $10,000 for the three months ended September 30, 2017 and 2016 , respectively, and $25,900 and $94,000 for the nine months ended September 30, 2017 and 2016 , respectively. During March 2016, the Company modified the vesting feature of an award granted to a director who decided to not stand for re-election at the Company’s 2016 annual meeting of stockholders. The modification of the award resulted in an additional $64,000 in stock-based compensation expense for the three months ended March 31, 2016. At the Company’s annual meeting of stockholders held on April 7, 2016, the Company’s stockholders approved the Natural Health Trends Corp. 2016 Equity Incentive Plan (the “2016 Plan”) to replace its 2007 Equity Incentive Plan. The 2016 Plan allows for the grant of various equity awards including incentive stock options, non-statutory options, stock, stock units, stock appreciation rights and other similar equity-based awards to the Company’s employees, officers, non-employee directors, contractors, consultants and advisors of the Company. Up to 2,500,000 shares of the Company’s common stock (subject to adjustment under certain circumstances) may be issued pursuant to awards granted. At September 30, 2017 , 2,393,873 shares remained available for issuance under the 2016 Plan. On January 24, 2017, the Company granted 56,260 shares of restricted common stock under the 2016 Plan to certain employees for the purpose of further aligning their interest with those of its stockholders and settling fiscal 2016 performance incentives totaling $1.4 million . The shares vest on a quarterly basis over three years and are subject to forfeiture in the event of the employee’s termination of service to the Company under specified circumstances. The following table summarizes the Company’s restricted stock activity under the 2016 Plan: Shares Wtd. Avg. Price at Date of Issuance Nonvested at December 31, 2016 38,256 $ 34.13 Granted 56,260 25.44 Vested (26,502 ) 29.58 Forfeited (1,148 ) 28.55 Nonvested at September 30, 2017 66,866 28.72 The following table summarizes the Company’s other restricted stock activity: Shares Wtd. Avg. Price at Date of Issuance Nonvested at December 31, 2016 22,348 $ 12.15 Granted — — Vested (16,455 ) 12.15 Forfeited (418 ) 12.28 Nonvested at September 30, 2017 5,475 12.15 As of September 30, 2017 , total unrecognized stock-based compensation expense related to non-vested restricted stock was $8,400 , which is expected to be recognized over a weighted-average period of 0.2 years . Accumulated Other Comprehensive Loss The changes in accumulated other comprehensive loss by component for the first nine months of 2017 were as follows (in thousands): Foreign Currency Translation Adjustment Unrealized Losses on Available-For-Sale Investments Total Balance, December 31, 2016 $ (805 ) $ (2 ) $ (807 ) Other comprehensive income (loss) 359 (10 ) 349 Amounts reclassified out of accumulated other comprehensive loss (258 ) — (258 ) Balance, September 30, 2017 $ (704 ) $ (12 ) $ (716 )

INCOME TAXES INCOME TAXES

INCOME TAXES INCOME TAXES	9 Months Ended
	Sep. 30, 2017
INCOME TAXES [Abstract]
Income Tax, Policy [Policy Text Block]	INCOME TAXES As a result of capital return activities approved by the Board of Directors during the first quarter of 2016 and anticipated future capital return activities, the Company determined that a portion of its current undistributed foreign earnings are no longer deemed reinvested indefinitely by its non-U.S. subsidiaries. The Company will continue to periodically reassess the needs of its foreign subsidiaries and update its indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, the Company expects to recognize additional income tax provision at the applicable U.S. corporate tax rate. As of September 30, 2017 , the Company has accrued tax liabilities for earnings that the Company plans to repatriate out of accumulated earnings in future periods. All undistributed earnings in excess of 50% of current earnings on an annual basis are intended to be reinvested indefinitely as of September 30, 2017 .

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Securities Class Action In January 2016, two putative securities class action complaints were filed against the Company and its top executives in the United States District Court for the Central District of California. On March 29, 2016, the Court consolidated these actions under the caption Ford v. Natural Health Trends Corp. , Case No. 2:16-cv-00255-TJH-AFMx, appointed two Lead Plaintiffs, Mahn Dao and Juan Wang, and appointed the Rosen Law Firm and Levi & Korsinsky LLP as co-Lead Counsel for the purported class. Plaintiffs filed a consolidated complaint on April 29, 2016. The consolidated complaint purports to assert claims on behalf of all persons who purchased or otherwise acquired our common stock between March 6, 2015 and March 15, 2016 under (i) Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder against the Company and Chris T. Sharng, Timothy S. Davidson and George K. Broady (together, the “Individual Defendants”), and (ii) Section 20(a) of the Securities Exchange Act of 1934 against the Individual Defendants. The consolidated complaint alleges, inter alia, that the Company made materially false and misleading statements regarding the legality of its business operations in China, including running an allegedly illegal multilevel marketing business. The consolidated complaint seeks an indeterminate amount of damages, plus interest and costs. The Company moved to dismiss the consolidated complaint on June 15, 2016. After full briefing and a hearing, the Court denied defendants’ motion to dismiss on December 5, 2016. On February 17, 2017, the Company filed an answer to the consolidated complaint. On April 14, 2017, the Court entered an order setting case management deadlines for the case, which included the conclusion of fact discovery in May 2018 and a final pretrial conference in August 2018. On July 10, 2017, the Court entered a stipulation between the parties, postponing all deadlines and staying the case for thirty days to allow the parties to engage in settlement discussions. On July 17, 2017, the parties reached an agreement in principle to settle the action. On July 18, 2017, the parties jointly filed a stipulation and proposed order with the Court, seeking to extend the stay for approximately sixty days to allow them an opportunity to negotiate the terms of a written settlement agreement and prepare and file the documentation necessary to obtain Court approval of the settlement. The Court entered the requested order on July 25, 2017, effecting a further stay of the case until September 25, 2017. The proposed class-wide settlement in the amount of $1.75 million was submitted to the Court for preliminary approval on October 3, 2017, but no hearing date has yet been set. If approved, the proposed settlement will be fully funded by the Company’s insurers. Defendants continue to believe that these claims are without merit and intend to vigorously defend against them if a settlement is not finalized and approved by the Court. Shareholder Derivative Claims In February 2016, a purported shareholder derivative complaint was filed in the Superior Court of the State of California, County of Los Angeles: Zhou v. Sharng . In March 2016, a purported shareholder derivative complaint was filed in the United States District Court for the Central District of California: Kleinfeldt v. Sharng (collectively the “Derivative Complaints”). The Derivative Complaints purport to assert claims for breach of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement and corporate waste against certain of the Company’s officers and directors. The Derivative Complaints also purport to assert fiduciary duty claims based on alleged insider selling and conspiring to enter into several stock repurchase agreements, which allegedly harmed the Company and its assets. The Derivative Complaints allege, inter alia, that the Company made materially false and misleading statements regarding the legality of its business operations in China, including running an allegedly illegal multi-level marketing business, and that certain officers and directors sold common stock on the basis of this allegedly material, adverse non-public information. The Derivative Complaints seek an indeterminate amount of damages, plus interest and costs, as well as various equitable remedies. On February 1, 2017, pursuant to a stipulation among the parties, the Los Angeles Superior Court entered a stay of the Zhou action pending conclusion of the related federal class action in the United States District Court for the Central District of California: Ford v. Natural Health Trends Corp. A nearly identical stipulated stay was entered in the Kleinfeldt case on February 28, 2017. The Company believes that these claims are without merit and intends to vigorously defend against them.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2017
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	RELATED PARTY TRANSACTIONS On April 29, 2015, the Company entered into a Royalty Agreement and License with Broady Health Sciences, L.L.C., a Texas limited liability company, (“BHS”) regarding the manufacture and sale of a product called Soothe ™. George K. Broady, a director of the Company and beneficial owner of more than 5% of its outstanding common stock, is owner of BHS. The Company began selling this product in the fourth quarter of 2012 with the permission of BHS. Under the agreement, the Company agreed to pay BHS a royalty of 2.5% of sales revenue in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide. Royalties expense recognized for the three months ended September 30, 2017 and 2016 were $100 and $700 , respectively, and $1,300 and $2,700 for the nine months ended September 30, 2017 and 2016 , respectively. The Company is not required to purchase any product under the agreement, and the agreement may be terminated at any time on 120 days ’ notice. Otherwise, the agreement terminates March 31, 2020. In February 2013, the Company entered into a Royalty Agreement and License with BHS regarding the manufacture and sale of a product called ReStor™. Under the agreement, the Company agreed to pay BHS a royalty of 2.5% of sales revenue in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide, with certain rights being exclusive outside the United States. On April 29, 2015, the Company and BHS amended the Royalty Agreement and License to change the royalty to a price per unit instead of 2.5% of sales revenue. Such provision was effective retroactively to January 1, 2015. Such royalties were $61,000 and $106,000 for the three months ended September 30, 2017 and 2016 , respectively, and $238,000 and $386,000 for the nine months ended September 30, 2017 and 2016 , respectively. The Company is not required to purchase any product under the agreement, and the agreement may be terminated at any time on 120 days ’ notice or, under certain circumstances, with no

SUBSEQUENT EVENT

SUBSEQUENT EVENT	9 Months Ended
	Sep. 30, 2017
Subsequent Events [Abstract]
SUBSEQUENT EVENT	SUBSEQUENT EVENT On October 30, 2017 , the Board of Directors declared a quarterly cash dividend of $0.12 and a special cash dividend of $0.15 on each share of common stock outstanding. Such dividends are payable on November 24, 2017 to stockholders of record on November 14, 2017

NATURE OF OPERATIONS, BASIS OF

NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION CONSOLIDATION	9 Months Ended
	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Principles of Consolidation	Principles of Consolidation

ACCOUNTING PRONOUNCEMENTS ACC18

ACCOUNTING PRONOUNCEMENTS ACCOUNTING PRONOUNCEMENTS	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	ACCOUNTING PRONOUNCEMENTS In November 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-18, Statement of Cash Flows - Restricted Cash , that requires amounts generally described as restricted cash or restricted cash equivalents be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The new standard will be effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, and early adoption is permitted. The adoption of this guidance is not expected to have a material impact on the Company’s consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting , that simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The new standard was effective for fiscal years beginning after December 15, 2016, including interim periods within those annual years, and early adoption was permitted. The Company adopted this guidance as of the quarter ended March 31, 2017. The adoption of this guidance did not have a material effect on the Company’s consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases , that requires organizations that lease assets, referred to as “lessees”, to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases with lease terms of more than 12 months. ASU 2016-02 will also require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases and will include qualitative and quantitative requirements. The new standard will be effective for fiscal years beginning after December 15, 2018, including interim periods within those annual years, and early application is permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements. In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes . Under this guidance, entities are required to present deferred tax assets and deferred tax liabilities as noncurrent in a classified balance sheet. This guidance was effective for annual and interim periods beginning after December 15, 2016, with early adoption permitted. Entities were permitted to adopt this guidance either prospectively or retrospectively. The Company elected to early adopt this guidance prospectively as of the quarter ended December 31, 2016. In July 2015, the FASB issued ASU No. 2015-11, Inventory: Simplifying the Measurement of Inventory. Under this guidance, inventory not measured using either the last in, first out (LIFO) or the retail inventory method are to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable cost of completion, disposal, and transportation. The new standard was effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years, with early adoption permitted. The Company adopted this guidance as of the quarter ended March 31, 2017. The adoption of this guidance did not have a material effect on the Company’s consolidated financial statements. In May 2014, the FASB issued ASU No. 2014-09, Revenue From Contracts With Customers , that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. It also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract. Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard. In July 2015, the FASB approved the deferral of the effective date for annual reporting periods that begin after December 15, 2017, including interim reporting periods. The adoption of this guidance is not expected to have a material impact on the Company’s consolidated financial statements.

NET INCOME PER COMMON SHARE N19

NET INCOME PER COMMON SHARE Net Income Per Common Share (Policies)	9 Months Ended
	Sep. 30, 2017
Earnings Per Share [Abstract]
Earnings Per Share, Policy [Policy Text Block]	Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized and the amount of tax benefit that would be recorded in additional paid-in capital when the award becomes deductible are assumed to be used to repurchase shares.

FAIR VALUE MEASUREMENTS (Polici

FAIR VALUE MEASUREMENTS (Policies)	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Cash and Cash Equivalents, Policy [Policy Text Block]	As of September 30, 2017 , cash and cash equivalents include the Company’s investments in debt securities, comprising municipal notes and bonds and corporate debt, money market funds and time deposits. The Company considers all highly liquid investments with original maturities of three months or less when purchased and have insignificant interest rate risk to be cash equivalents. Debt securities classified as cash equivalents are required to be accounted for in accordance with ASC 320, Investments - Debt and Equity Securities . As such, the Company determined its investments in debt securities held at September 30, 2017
Fair Value of Financial Instruments, Policy [Policy Text Block]	The carrying amounts of the Company’s financial instruments, including cash and cash equivalents and accounts payable, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents. The Company’s cash equivalents are valued based on level 1 inputs which consist of quoted prices in active markets.

NET INCOME PER COMMON SHARE N21

NET INCOME PER COMMON SHARE Net Income Per Common Share (Tables)	9 Months Ended
	Sep. 30, 2017
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	The following tables illustrate the computation of basic and diluted net income per common share for the periods indicated (in thousands, except per share data): Three Months Ended September 30, 2017 2016 Income (Numerator) Shares (Denominator) Per Share Amount Income (Numerator) Shares (Denominator) Per Share Amount Basic net income per common share: Net income available to common stockholders $ 7,338 11,258 $ 0.65 $ 12,557 11,209 $ 1.12 Effect of dilutive securities: Non-vested restricted stock — 18 — 23 Diluted net income per common share: Net income available to common stockholders plus assumed conversions $ 7,338 11,276 $ 0.65 $ 12,557 11,232 $ 1.12 Nine Months Ended September 30, 2017 2016 Income (Numerator) Shares (Denominator) Per Share Amount Income (Numerator) Shares (Denominator) Per Share Amount Basic net income per common share: Net income available to common stockholders $ 28,066 11,244 $ 2.50 $ 36,038 11,437 $ 3.15 Effect of dilutive securities: Non-vested restricted stock — 25 — 26 Diluted net income per common share: Net income available to common stockholders plus assumed conversions $ 28,066 11,269 $ 2.49 $ 36,038 11,463 $ 3.14
Earnings Per Share [Text Block]	NET INCOME PER COMMON SHARE Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized and the amount of tax benefit that would be recorded in additional paid-in capital when the award becomes deductible are assumed to be used to repurchase shares. The following tables illustrate the computation of basic and diluted net income per common share for the periods indicated (in thousands, except per share data): Three Months Ended September 30, 2017 2016 Income (Numerator) Shares (Denominator) Per Share Amount Income (Numerator) Shares (Denominator) Per Share Amount Basic net income per common share: Net income available to common stockholders $ 7,338 11,258 $ 0.65 $ 12,557 11,209 $ 1.12 Effect of dilutive securities: Non-vested restricted stock — 18 — 23 Diluted net income per common share: Net income available to common stockholders plus assumed conversions $ 7,338 11,276 $ 0.65 $ 12,557 11,232 $ 1.12 Nine Months Ended September 30, 2017 2016 Income (Numerator) Shares (Denominator) Per Share Amount Income (Numerator) Shares (Denominator) Per Share Amount Basic net income per common share: Net income available to common stockholders $ 28,066 11,244 $ 2.50 $ 36,038 11,437 $ 3.15 Effect of dilutive securities: Non-vested restricted stock — 25 — 26 Diluted net income per common share: Net income available to common stockholders plus assumed conversions $ 28,066 11,269 $ 2.49 $ 36,038 11,463 $ 3.14

BALANCE SHEET COMPONENTS Bala22

BALANCE SHEET COMPONENTS Balance Sheet Components (Tables)	9 Months Ended
	Sep. 30, 2017
Balance Sheet Components [Abstract]
Schedule of Additional Balance Sheet Components [Table Text Block]	The components of certain balance sheet amounts are as follows (in thousands): September 30, 2017 December 31, 2016 Cash and cash equivalents: Cash $ 53,536 $ 52,453 Cash equivalents 73,417 73,468 $ 126,953 $ 125,921 Other accrued expenses: Sales returns $ 574 $ 1,632 Employee-related 6,236 10,541 Warehousing, inventory-related and other 1,735 2,816 $ 8,545 $ 14,989

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Available-for-sale Securities [Table Text Block]	Available-for-sale investments included in cash equivalents at the end of each period were as follows (in thousands): September 30, 2017 December 31, 2016 Adjusted Cost Gross Unrealized Gains (Losses) Fair Value Adjusted Cost Gross Unrealized Losses Fair Value Municipal bonds and notes $ 2,751 $ 1 $ 2,752 $ 43,490 $ — $ 43,490 Corporate debt securities 24,194 (13 ) 24,181 1,673 (2 ) 1,671 Financial institution instruments 46,484 — 46,484 28,307 — 28,307 Total available-for-sale investments $ 73,429 $ (12 ) $ 73,417 $ 73,470 $ (2 ) $ 73,468

STOCKHOLDERS' EQUITY RESTRICTED

STOCKHOLDERS' EQUITY RESTRICTED STOCK ACTIVITY (Tables)	9 Months Ended
	Sep. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Restricted Stock Activity	The following table summarizes the Company’s other restricted stock activity: Shares Wtd. Avg. Price at Date of Issuance Nonvested at December 31, 2016 22,348 $ 12.15 Granted — — Vested (16,455 ) 12.15 Forfeited (418 ) 12.28 Nonvested at September 30, 2017 5,475 12.15 Shares Wtd. Avg. Price at Date of Issuance Nonvested at December 31, 2016 38,256 $ 34.13 Granted 56,260 25.44 Vested (26,502 ) 29.58 Forfeited (1,148 ) 28.55 Nonvested at September 30, 2017 66,866 28.72

STOCKHOLDERS' EQUITY ACCUMULATE

STOCKHOLDERS' EQUITY ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)	9 Months Ended
	Sep. 30, 2017
Accumulated Other Comprehensive Income (Loss) [Line Items]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	The changes in accumulated other comprehensive loss by component for the first nine months of 2017 were as follows (in thousands): Foreign Currency Translation Adjustment Unrealized Losses on Available-For-Sale Investments Total Balance, December 31, 2016 $ (805 ) $ (2 ) $ (807 ) Other comprehensive income (loss) 359 (10 ) 349 Amounts reclassified out of accumulated other comprehensive loss (258 ) — (258 ) Balance, September 30, 2017 $ (704 ) $ (12 ) $ (716 )

STOCKHOLDERS' EQUITY Dividends

STOCKHOLDERS' EQUITY Dividends (Tables)	9 Months Ended
	Sep. 30, 2017
Dividends [Abstract]
Dividends Declared [Table Text Block]	The following table summarizes the Company’s cash dividend activity for the nine months ended September 30, 2017 (in thousands, except per share data): Declaration Date Per Share Amount Record Date Payment Date July 31, 2017 (special) $ 0.25 $ 2,833 August 21, 2017 August 31, 2017 July 31, 2017 0.11 1,246 August 21, 2017 August 31, 2017 April 24, 2017 (special) 0.35 3,964 May 9, 2017 May 19, 2017 April 24, 2017 0.10 1,133 May 9, 2017 May 19, 2017 January 24, 2017 (special) 0.35 3,962 February 21, 2017 March 3, 2017 January 24, 2017 0.09 1,019 February 21, 2017 March 3, 2017 $ 1.25 $ 14,157

NET INCOME PER COMMON SHARE N27

NET INCOME PER COMMON SHARE Net Income Per Common Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Earnings Per Share [Abstract]
Net Income (Loss) Available to Common Stockholders, Basic	$ 7,338	$ 12,557	$ 28,066	$ 36,038
Weighted Average Number of Shares Outstanding, Basic	11,258	11,209	11,244	11,437
Earnings Per Share, Basic	$ 0.65	$ 1.12	$ 2.50	$ 3.15
Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements	18	23	25	26
Net Income (Loss) Available to Common Stockholders, Diluted	$ 7,338	$ 12,557	$ 28,066	$ 36,038
Weighted Average Number of Shares Outstanding, Diluted	11,276	11,232	11,269	11,463
Earnings Per Share, Diluted	$ 0.65	$ 1.12	$ 2.49	$ 3.14

BALANCE SHEET COMPONENTS Bala28

BALANCE SHEET COMPONENTS Balance Sheet Components (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2015
Condensed Balance Sheet Statements, Captions [Line Items]
Cash and Cash Equivalents, at Carrying Value	$ 126,953	$ 125,921	$ 114,500	$ 104,914
Accrued Sales Returns	574	1,632
Accrued Employee Benefits, Current	6,236	10,541
Accrued Warehousing And Inventory Related Expense	1,735	2,816
Other Accrued Liabilities, Current	8,545	14,989
Cash Equivalents [Member]
Condensed Balance Sheet Statements, Captions [Line Items]
Cash and Cash Equivalents, at Carrying Value	73,417	73,468
Cash [Member]
Condensed Balance Sheet Statements, Captions [Line Items]
Cash and Cash Equivalents, at Carrying Value	$ 53,536	$ 52,453

FAIR VALUE MEASUREMENTS (Detail

FAIR VALUE MEASUREMENTS (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Amortized Cost Basis	$ 73,429	$ 73,470
Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax	(12)	(2)
Available-for-sale Securities	73,417	73,468
Municipal Bonds and Notes [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Amortized Cost Basis	2,751	43,490
Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax	1	0
Available-for-sale Securities	2,752	43,490
Corporate Debt Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Amortized Cost Basis	24,194	1,673
Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax	(13)	(2)
Available-for-sale Securities	24,181	1,671
Financial Institution Instruments [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Amortized Cost Basis	46,484	28,307
Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax	0	0
Available-for-sale Securities	$ 46,484	$ 28,307

STOCKHOLDERS' EQUITY NARRATIVE

STOCKHOLDERS' EQUITY NARRATIVE (Details) - USD ($)	Jul. 31, 2017	Apr. 24, 2017	Jan. 24, 2017	Apr. 08, 2016	Sep. 30, 2017	Sep. 30, 2016	Mar. 31, 2016	Sep. 30, 2017	Sep. 30, 2016	Apr. 07, 2016	Jan. 12, 2016	Jul. 28, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Dividends, Per Share, Declared	$ 0.11	$ 0.10	$ 0.09		$ 0.36	$ 0.07		$ 1.25	$ 0.18
CommonStockSpecialDividendsPerShareDeclared	$ 0.25	$ 0.35	$ 0.35
Dividends, Common Stock, Cash	$ 2,833,000	$ 3,964,000	$ 3,962,000
Dividends, Cash	$ 1,246,000	$ 1,133,000	$ 1,019,000					$ 14,157,000
Share-based compensation expense					$ 8,600	$ 10,000		25,900	$ 94,000
Additional stock-based compensation expense							$ 64,000
Stock repurchase program, amount authorized											$ 70,000,000	$ 15,000,000
Stock Repurchase Program, Remaining Authorized Repurchase Amount					32,000,000			$ 32,000,000
Common Stock, Dividends, Per Share, Cash Paid								$ 1.25
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)				56,260				0
Award vesting period (in years)				3 years
Share-based compensation expense not yet recognized					$ 8,400			$ 8,400
Recognition period for compensation costs not yet recognized (in years)								2 months 12 days
Equity Incentive Plan 2016 | Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized										2,500,000
Equity Incentive Plan 2016 | Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)								56,260

STOCKHOLDERS' EQUITY RESTRICT31

STOCKHOLDERS' EQUITY RESTRICTED STOCK ACTIVITY (Details) - USD ($) $ / shares in Units, $ in Millions	Jan. 24, 2017	Apr. 08, 2016	Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant			2,393,873
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Stock Issued During Period, Value, Restricted Stock Award, Gross	$ 1.4
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Nonvested, beginning balance (in shares)			22,348
Granted (in shares)		56,260	0
Vested (in shares)			(16,455)
Stock Issued During Period, Shares, Restricted Stock Award, Forfeited			(418)
Nonvested, ending balance (in shares)			5,475
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Nonvested, beginning balance (in dollars per share)			$ 12.15
Granted (in dollars per share)			0
Vested (in dollars per share)			12.15
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value			12.28
Nonvested, ending balance (in dollars per share)			$ 12.15
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		3 years
Restricted Stock | Equity Incentive Plan 2016
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Nonvested, beginning balance (in shares)			38,256
Granted (in shares)			56,260
Vested (in shares)			(26,502)
Stock Issued During Period, Shares, Restricted Stock Award, Forfeited			(1,148)
Nonvested, ending balance (in shares)			66,866
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Nonvested, beginning balance (in dollars per share)			$ 34.13
Granted (in dollars per share)			25.44
Vested (in dollars per share)			29.58
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value			28.55
Nonvested, ending balance (in dollars per share)			$ 28.72

STOCKHOLDERS' EQUITY ACCUMULA32

STOCKHOLDERS' EQUITY ACCUMULATED OTHER COMPREHENSIVE LOSS (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2017USD ($)
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance, December 31, 2016	$ (807)
Balance, March 31, 2017	(716)
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance, December 31, 2016	(805)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	359
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent	(258)
Balance, March 31, 2017	(704)
Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance, December 31, 2016	(2)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(10)
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent	0
Balance, March 31, 2017	(12)
AOCI Attributable to Parent [Member]
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance, December 31, 2016	(807)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	349
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent	(258)
Balance, March 31, 2017	$ (716)

COMMITMENTS AND CONTINGENCIES N

COMMITMENTS AND CONTINGENCIES NARRATIVE (Details) $ in Thousands	1 Months Ended	9 Months Ended
	Jan. 31, 2016complaint	Sep. 30, 2017USD ($)
Loss Contingencies [Line Items]
Litigation Settlement, Amount | $		$ 1,750
Securities Class Action
Loss Contingencies [Line Items]
Number of complaints | complaint	2

RELATED PARTY TRANSACTIONS NARR

RELATED PARTY TRANSACTIONS NARRATIVE (Detail) - Broady Health Sciences - USD ($)	Apr. 29, 2015	Feb. 28, 2013	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Soothe
Related Party Transaction [Line Items]
Royalty rate	2.50%
Royalty expense			$ 100	$ 700	$ 1,300	$ 2,700
Number of days for termination notice	120 days
ReStore
Related Party Transaction [Line Items]
Royalty rate		2.50%
Royalty expense			$ 61,000	$ 106,000	$ 238,000	$ 386,000
Number of days for termination notice		120 days

SUBSEQUENT EVENT - NARRATIVE (D

SUBSEQUENT EVENT - NARRATIVE (Details) - $ / shares	Oct. 30, 2017	Jul. 31, 2017	Apr. 24, 2017	Jan. 24, 2017	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Subsequent Event [Line Items]
Common Stock, Dividends, Per Share, Declared		$ 0.11	$ 0.10	$ 0.09	$ 0.36	$ 0.07	$ 1.25	$ 0.18
CommonStockSpecialDividendsPerShareDeclared		$ 0.25	$ 0.35	$ 0.35
Subsequent Event
Subsequent Event [Line Items]
Common Stock, Dividends, Per Share, Declared	$ 0.12
CommonStockSpecialDividendsPerShareDeclared	$ 0.15